- Report
- February 2024
- 70 Pages
Japan
From €4541EUR$4,750USD£3,902GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4541EUR$4,750USD£3,902GBP
- Report
- February 2024
- 70 Pages
South Africa
From €4541EUR$4,750USD£3,902GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4541EUR$4,750USD£3,902GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4541EUR$4,750USD£3,902GBP
- Report
- February 2024
- 70 Pages
India
From €4541EUR$4,750USD£3,902GBP
- Report
- February 2024
- 70 Pages
New Zealand
From €4541EUR$4,750USD£3,902GBP
- Report
- October 2022
- 70 Pages
Africa
From €4541EUR$4,750USD£3,902GBP
- Report
- August 2020
- 150 Pages
Global
From €4063EUR$4,250USD£3,492GBP
- Report
- October 2019
- 125 Pages
Canada
From €4541EUR$4,750USD£3,902GBP
- Report
- October 2022
- 138 Pages
Global
From €4254EUR$4,450USD£3,656GBP
- Report
- May 2020
- 121 Pages
Global
From €4159EUR$4,350USD£3,574GBP
- Drug Pipelines
- February 2019
- 54 Pages
Global
From €9560EUR$10,000USD£8,215GBP
- Drug Pipelines
- February 2018
- 207 Pages
Global
From €21032EUR$22,000USD£18,074GBP
- Report
- February 2021
- 90 Pages
Global
€21032EUR$22,000USD£18,074GBP
- Report
- January 2019
- 35 Pages
Global
From €956EUR$1,000USD£822GBP
Farxiga is a medication used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which work by blocking the reabsorption of glucose in the kidneys, allowing it to be excreted in the urine. Farxiga is also used to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.
Farxiga is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to help regulate hormones and metabolism, and can be taken orally or injected.
Companies in the Farxiga market include AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Sanofi. Show Less Read more